Clinical Trial Update: Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of talazoparib in combination with gemcitabine and cisplatin for advanced solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Platinol (cisplatin)
• Talzenna (talazoparib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 | Status: WITHDRAWN